Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Takeda Begins Japan Trials Of Mood, Anxiety Drugs From Denmark

This article was originally published in PharmAsia News

Executive Summary

Takeda Pharmaceuticals says it has begun trials of the first of two drugs licensed from H. Lundbeck of Denmark to treat mood and anxiety disorders. As LuAA21004, the first of the two drugs, enters trials, Takeda plans to develop LuAA24530. The drugs have differing molecular structures and are intended to be sold along side each other. Both drugs are well into Phase II trials in Europe. (Click here for more - a subscription may be required

Latest Headlines
See All
UsernamePublicRestriction

Register

SC071057

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel